Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): A multicountry open-label randomised controlled trial

The Lancet

Volumn 387, Issue 10024, 2016, Pages 1198-1209

  Hosseinipour, Mina C ^a,b   Bisson, Gregory P ^c   Miyahara, Sachiko ^d   Sun, Xin ^d   Moses, Agnes ^a   Riviere, Cynthia ^e   Kirui, Fredrick K ^f   Badal Faesen, Sharlaa ^g   Lagat, David ^h   Nyirenda, Mulinda ⁱ   Naidoo, Kogieleum ^j   Hakim, James ^k   Mugyenyi, Peter ^l   Henostroza, German ^m   Leger, Paul D ^e   Lama, Javier R ⁿ   Mohapi, Lerato ^g   Alave, Jorge ⁿ   Mave, Vidya ^o   Veloso, Valdilea G ^p   Pillay, Sandy ^q   Kumarasamy, Nagalingeswaran ^r   Bao, Jing ^s   Hogg, Evelyn ^t   Jones, Lynne ^u   Zolopa, Andrew ^v   Kumwenda, Johnstone ⁱ   Gupta, Amita ^w   more..

^a UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HARVARD UNIVERSITY   (United States)

^e Centers Institute of Infectious Diseases and Reproductive Health   (Haïti)

^f KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^g UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^h MOI UNIVERSITY   (Kenya)

ⁱ Johns Hopkins Project   (Malawi)

^j UNIVERSITY OF KWAZULU NATAL   (South Africa)

^k UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^l JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^m CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

ⁿ ASOCIACIÓN CIVIL IMPACTA SALUD Y EDUCACIÓN   (Peru)

^o B J MEDICAL COLLEGE   (India)

^p Funda??o Oswaldo Cruz   (Brazil)

^q DURBAN UNIVERSITY OF TECHNOLOGY   (South Africa)

^r VHS Medical Centre India   (India)

^s HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^t SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^u FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^v STANFORD UNIVERSITY   (United States)

^w JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BICARBONATE; BILIRUBIN; CALCIUM; CARBON DIOXIDE; CREATININE; ETHAMBUTOL; ETHAMBUTOL PLUS ISONIAZID; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; SODIUM; STREPTOMYCIN; TENOFOVIR; URIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BICARBONATE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CALCIUM BLOOD LEVEL; CARBON DIOXIDE BLOOD LEVEL; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRYPTOCOCCAL MENINGITIS; DISEASE COURSE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTENTION TO TREAT ANALYSIS; KAPOSI SARCOMA; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; NEPHROTOXICITY; NEUTROPHIL COUNT; OPEN STUDY; OUTPATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SIDE EFFECT; SODIUM BLOOD LEVEL; SURVIVAL; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; TRAFFIC ACCIDENT; TREATMENT DURATION; URIC ACID BLOOD LEVEL; WEIGHT REDUCTION; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CLINICAL TRIAL; HIV INFECTIONS; IMMUNOLOGY; KAPLAN MEIER METHOD; MULTICENTER STUDY; OUTPATIENT DEPARTMENT; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; ISONIAZID; KAPLAN-MEIER ESTIMATE; MALE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84961242166     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)00546-8     Document Type: Article

References (30)

1. UNAIDS How AIDS changed everything: MDG 6: 15 years, 15 lessons of hope from the AIDS response. Fact Sheet http://www.unaids.org/sites/default/files/media-asset/20150714-FS-MDG6-Report-en.pdf 2015 (accessed July 14, 2015).
2. A Gupta, G Nadkarni, WT Yang et al. Early mortality in adults initiating antiretroviral therapy (art) in low- and middle-income countries (LMIC): a systematic review and meta-analysis PLoS One 6 2011 e28691
3. A Gupta, R Wood, R Kaplan, LG Bekker, SD Lawn Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa PLoS One 8 2013 e55824
4. SD Lawn, M Badri, R Wood Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort AIDS 19 2005 2109 2116
5. MW Brinkhof, M Egger, A Boulle et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries Clin Infect Dis 45 2007 1518 1521
6. RK Gupta, SB Lucas, KL Fielding, SD Lawn Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis AIDS 29 2015 1987 2002
7. H Getahun, W Kittikraisak, CM Heilig et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies PLoS Med 8 2011 e1000391
8. S Singhal, SN Mahajan, SK Diwan, A Gaidhane, ZS Quazi Correlation of sputum smear status with CD4 count in cases of pulmonary tuberculosis and HIV co-infected patients - a hospital based study in a rural area of Central India Indian J Tuberc 58 2011 108 112
9. LE Scott, K McCarthy, N Gous et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study PLoS Med 8 2011 e1001061
10. L Fenner, M Ballif, C Graber et al. Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening PLoS One 8 2013 e77697
11. G Theron, L Zijenah, D Chanda et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial Lancet 383 2014 424 435
12. GJ Churchyard, WS Stevens, LD Mametja et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF Lancet Glob Health 3 2015 e450 e457
13. HS Cox, S Mbhele, N Mohess et al. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial PLoS Med 11 2014 e1001760
14. World Health Organization Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: what's new http://www.avac.org/sites/default/files/resource-files/guidelines-Nov2015.pdf 2015 (accessed Jan 30, 2016).
15. Temprano ANRS Study Group A trial of early antiretrovirals and isoniazid preventive therapy in Africa N Engl J Med 2015 10.1056/NEJMoa1507198 published online Aug 27.
16. RM Houben, T Sumner, AD Grant, RG White Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings Proc Natl Acad Sci USA 111 2014 5325 5330
17. SP Koenig, C Riviere, P Leger et al. High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy Clin Infect Dis 48 2009 829 831
18. S Mfinanga, D Chanda, SL Kivuyo et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial Lancet 385 2015 2173 2182
19. Dart Trial Team P Mugyenyi, AS Walker et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial Lancet 375 2010 123 131
20. A Jindani, CJ Dore, DA Mitchison Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days Am J Respir Crit Care Med 167 2003 1348 1354
21. C Akolo, I Adetifa, S Shepperd, J Volmink Treatment of latent tuberculosis infection in HIV infected persons Cochrane Database Syst Rev 1 2010 CD000171.
22. T Samandari, TB Agizew, S Nyirenda et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial Lancet 377 2011 1588 1598
23. MX Rangaka, RJ Wilkinson, A Boulle et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial Lancet 384 2014 682 690
24. S Charalambous, AD Grant, C Innes et al. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme AIDS 24 suppl 5 2010 S5 13
25. JE Golub, P Pronyk, L Mohapi et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort AIDS 23 2009 631 636
26. B Durovni, V Saraceni, LH Moulton et al. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial Lancet Infect Dis 13 2013 852 858
27. SD Lawn, R Wood, KM De Cock, K Kranzer, JJ Lewis, GJ Churchyard Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources Lancet Infect Dis 10 2010 489 498
28. IeDea ARTC Collaborations, D Avila et al. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries J Acquir Immune Defic Syndr 65 2014 e8 16
29. SD Lawn, AD Kerkhoff, M Vogt, R Wood Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study Lancet Infect Dis 12 2012 201 209
30. JG Peter, LS Zijenah, D Chanda et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial Lancet 2016 published online March 9. http://dx.doi.org/10.1016/S0140-6736(15)01092-2